HKPD vs NUVB

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus 21. 7% for Hong Kong Pharma Digital Technology Holdings Limited (HKPD). Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nuvation Bio Inc.

(NUVB) delivered a total return of -54. 3%, compared to -77. 0% for Hong Kong Pharma Digital Technology Holdings Limited (HKPD). Over 10 years, the gap is even starker: NUVB returned -49. 6% versus HKPD's -77. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hong Kong Pharma Digital Technology Holdings Limited (HKPD) is the lower-risk stock at 1.

66β versus Nuvation Bio Inc. 's 2. 04β — meaning NUVB is approximately 23% more volatile than HKPD relative to the S&P 500. On balance sheet safety, Nuvation Bio Inc. (NUVB) carries a lower debt/equity ratio of 3% versus 48% for Hong Kong Pharma Digital Technology Holdings Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus 21. 7% for Hong Kong Pharma Digital Technology Holdings Limited (HKPD). On earnings-per-share growth, the picture is similar: Nuvation Bio Inc. grew EPS 71. 6% year-over-year, compared to -101. 7% for Hong Kong Pharma Digital Technology Holdings Limited. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hong Kong Pharma Digital Technology Holdings Limited (HKPD) is the more profitable company, earning -0.

1% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps -0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HKPD leads at 0. 7% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hong Kong Pharma Digital Technology Holdings Limited (HKPD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HKPD: -77. 0%, NUVB: -49. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HKPD (Industrials) and NUVB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.